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Symptomatic chronic subdural haematoma (CSDH) will become an 
increasingly common presentation in neurosurgical practice as the population 
ages, but quality evidence remains lacking to guide the optimal management 
of these patients. The British Neurosurgical Trainee Research Collaborative 
(BNTRC) was established by neurosurgical trainees in 2012 to improve 
research by combining the efforts of trainees in each of the UK and Ireland’s 
Neurosurgical Units. We present the first study by the BNTRC that describes 
current management and outcomes for patients with CSDH throughout the UK 
and Ireland. This provides a resource both for current clinical practice and 




Data on management and outcomes for patients with CSDH referred to UK 
and Ireland Neurosurgical Units were collected prospectively over an 8-month 
period and audited against criteria predefined from the literature; NSU 
mortality <5%, NSU morbidity <10%, symptomatic recurrence within 60 days 
requiring repeat surgery <20%, and unfavourable functional status (mRS 4-6) 




Data from 1205 patients in 26 NSUs were collected. Burr hole craniostomy 
was the most common procedure (89%) and symptomatic recurrence requiring 
repeat surgery within 60 days was observed in 9%. Criteria on mortality (2%), 
rate of recurrence (9%) and unfavourable functional outcome (22%) were met, 




demonstrated that failure to leave a drain intra-operatively independently 
predicted recurrence and unfavourable functional outcome (p=0.011, p=0.048, 
respectively). Increasing patient age (p<0·00001), post-operative bed rest 
(p=0.019) and use of a single burr hole (p=0.020) independently predicted 
unfavourable functional outcomes, but prescription of high flow oxygen or pre-




This is the largest prospective CSDH study and helps establish national 
standards. It has confirmed in a real-word setting the effectiveness of placing a 
subdural drain. Our study identified a number of modifiable prognostic factors, 
but questions the necessity of some common aspects of CSDH management, 
such as enforced post-operative bed rest. Future studies should seek to 
establish how we can optimise peri-operative care of patients with CSDH to 
reduce morbidity as well as minimize CSDH recurrence. The BNTRC is unique 
worldwide, conducting multi-centre trainee-led research and audit. This study 
demonstrates that collaborative research networks are powerful tools to 
















Chronic subdural haematoma (CSDH) is a collection of liquefied blood 
between the dura and arachnoid layer of the brain. The incidence is 8·2/ 
100,000/year after 70 years of age. 2 With an ageing population a rise in 
CSDH prevalence is anticipated. Spontaneous resolution can occur, but 
surgical evacuation is indicated in patients who deteriorate or do not improve. 
However, there is little Class I evidence describing optimal surgical and peri-
operative management strategies.  
 
The three most common surgical techniques to treat CSDH are twist-drill 
craniostomy (TDC), burr-hole craniostomy (BHC), and craniotomy. Whilst all 
three techniques have approximately the same mortality (2-4%), craniotomy 
has significantly higher morbidity, and TDC has a higher rate of recurrence, 
suggesting BHC is the preferred technique. 25 In contrast, a more recent meta-
analysis concluded TDC should be first-line treatment, with craniotomy 
reserved for symptomatic recurrence. 8 
 
Other aspects of peri-operative and post-operative management may also 
influence outcome. A randomised controlled trial (RCT) demonstrated that 
subdural drains left in-situ after BHC reduced CSDH recurrence requiring re-
drainage (9·3 vs. 24·0% recurrence with/without drain). 21 The benefit of drains 
was confirmed in a recent meta-analysis. 3 However, conflicting evidence for 
other aspects of CSDH management leads to considerable variation in 
practice. For example, the optimal number of burr holes (one vs. two) or the 
benefit of using intra-operative irrigation is uncertain. 12,19,23 Post-operatively 
there is contradictory advice about the relative risks and benefits of bed rest 
versus early mobilization. 1,15,17 The benefit of corticosteroids as either a 
primary treatment or an adjunct to surgery remains unclear. 6,26 Opinions also 
vary regarding the need to administer agents to mitigate the biological effects 




suggest anti-platelet and anti-coagulant use pre-operatively is associated with 
higher rates of CSDH recurrence.4,9,22 Conversely, a retrospective study of 58 
patients suggested that early surgery for patients taking anti-platelets without 
drug cessation or platelet infusion may be safe. 18 
 
Patients with CSDH would benefit from a stronger evidence base for their 
management. The present study aims to present the clinical, management and 
outcome characteristics of patients with CSDH across the UK and Ireland. 
From this data we aimed to identify variables independently associated with 
symptomatic CSDH recurrence and unfavourable outcomes that could be 
interrogated in future studies. This was the first study to be conducted by the 





We conducted a nationwide, multi-center, prospective cohort study to describe 
the clinical characteristics of patients with CSDH, variation in operative and 
peri-operative strategies, and to ascertain short-term outcomes evaluated 
against ‘best-practice’ criteria determined from review of the published 
literature. The Strengthening the Reporting of Observational studies in 
Epidemiology (STROBE) checklist was used in preparation of this manuscript. 
24 
 
PARTICIPANTS AND STUDY SETTINGS 
Study participants were identified and enrolled at 26 of the 33 UK and Ireland 
neurosurgical units (NSUs) between May 2013 and January 2014. Eligibility 
criteria were age over 16, presentation with a primary or recurrent CSDH 
confirmed on cranial imaging, and referral to a participating NSU. CSDH was 
defined radiologically as a predominantly hypodense, isodense or mixed 




operation or during subsequent management were excluded (e.g. vascular 
malformations, subdural empyema). The study protocol was approved by the 
Academic Committee of the Society of British Neurological Surgeons (SBNS) 
and has been published previously.7 The study was supported by the SBNS 
and formed part of the Neurosurgical National Audit Programme (NNAP). 
 
OUTCOME MEASURES AND AUDIT STANDARDS 
Audit standards were determined from the literature as described previously;7 
NSU mortality <5%, NSU morbidity <10%, symptomatic recurrence within 60 
days requiring repeat surgery <20% and unfavourable functional status (mRS 
4-6) at NSU discharge <30%. 
 
DATA COLLECTION 
The BNTRC is a network of neurosurgical trainees and supervising 
consultants in each Neurosurgical Unit (NSU) in the UK and Ireland. Local 
trainee investigators identified patients at the time of admission to the NSU 
from on-call referral databases or theatre operative logbooks. Patient 
demographics, baseline characteristics including medical co-morbidities and 
relevant medication history, and details of pre-, intra- and post-operative 
management were collected. A minimum data set including baseline 
characteristics and proposed management were collected for patients referred 
to but not transferred into the NSU. Re-operation within 60 days of index 
admission was identified and recorded. The modified Rankin Scale (mRS) 
score at discharge from the NSU, morbidity and mortality in the NSU, 
destination at discharge from the NSU, and length of stay in the NSU, were 
also recorded. 
 
Data were submitted to a secure online database maintained by the Outcome 
Registry Intervention and Operation Network (ORION) at the University of 
Cambridge. The ORION database complies with Department of Health 




patient healthcare data set out in the Information Governance Toolkit of the 
Health and Social Care Information Centre.  Each NSU was the data controller 




Anonymised data were collated and checked for errors prior to analysis. 
Patients with missing data sets were excluded if the missing data was relevant 
to that particular analysis. Data were analysed according to the pre-defined 
audit standards using one-sample tests. Multivariable logistic regression 
models were used to assess the impact of variables on outcome and odds 






Data was collected on 1205 patients with CSDH referred to 26 NSUs; 
recruitment per unit ranged from 4-175 patients (mean 46 patients). Of 1205 
patients referred, 823 (68·3%) were accepted for NSU admission. The 
remaining 382 patients were managed at their referring hospital; twenty-four of 
these patients were subsequently transferred to the NSU, but have been 
excluded from the outcome analysis because of incomplete data. The 
commonest reason for not being transferred was that the subdural collection 
was considered small and insufficient to explain a patient’s symptoms, or that 
the patient was asymptomatic (Table 1). 
 
  
BASELINE CLINICAL CHARACTERISTICS OF TRANSFERRED PATIENTS 
The median age of patients admitted was 77 years (range 20-99). Sixty-eight 




the preceding 3 months. Demographic and baseline characteristics of patients 
are listed in Table 2. 
 
Cognitive impairment was the most frequent presenting symptom of 
transferred patients (58%), followed by hemiparesis (41%) and headache 
(41%) (Table 2). The majority of patients had a GCS of 13-15 (88%), not 
significantly different to non-transferred patients (89%). Patient’s functional 
status on admission was determined using the mRS and the median score 
was 3.  
 
 
MANAGEMENT OF PATIENTS TRANSFERRED TO A NSU 
  
Steroid Use 
Twenty-six patients (3%) received a course of dexamethasone. Sixteen (2%) 
as the primary treatment modality for a median of 6·5 days (range 3-21 days) 
with a median dose of 4mg per day (range 4-16mg). Ten patients (1%) as 
adjuvant treatment peri-operatively for a median of 6 days (range 1-40) with a 
median dose of 8mg per day (range 4-12mg). Of the 382 patients not 
transferred steroid therapy was recommended in 39 cases (10%).  
  
Perioperative clotting  
Of the patients transferred, 356/823 (43%) were prescribed anticoagulant or 
antiplatelet medication at the time of referral: 171 aspirin (21%), 160 warfarin 
(19%), 36 clopidogrel (4%), 6 dipyridamole (1%) and 12 ‘other’ medications 
not listed (1%).  Aspirin was discontinued a median of 3 days prior to surgery 
(range 0-44 days). Of the patients taking aspirin, 49/171 (28.7%) received a 
transfusion of platelets preoperatively. For patients taking warfarin (n=160), 
the most common reversal strategies were vitamin K + clotting factors (82), 
vitamin K alone (28) or clotting factors alone (20).  Reversal treatment was not 






Surgical procedures were performed on 787 of 823 patients (94%); 76% by 
registrars, 21% by senior house officers, 3% by consultants. Most operations 
were performed under general anaesthesia (93%). 
  
Burr hole craniostomy (BHC) was the most frequent procedure (700/787; 
89%), followed by craniotomy (72/787; 9%) and TDC in just one case 
(<1%); the remaining 14 patients had a craniectomy, or BHC and craniotomy 
on different sides. Unilateral BHC was most commonly performed using two-
burr holes (89%); 10% had a single burr hole. Burr holes were irrigated 
intraoperatively to remove the collection in 99% of cases and a drain was used 
in 85% of cases, most often sited subdurally (92%) rather than subgaleally. 
Drains were left in-situ for 48 hours (68%) or 24-hours (28%). 
 
Postoperative management 
Postoperative bed rest was prescribed in 61% of patients after BHC (median 
12-24 hours). Only 10% of patients undergoing BHC were prescribed high-flow 
oxygen postoperatively. Post-operative cranial imaging was performed in 380 
(48%) patients after surgery, of which the investigation was described as 





Outcomes were determined against the previously described criteria.  
 
Mortality (Audit standard – all cause mortality in NSU <5%) 
Mortality and morbidity data was reported for 798/823 transferred patients. 
Eighteen patients (2%) died during the study (18/798).  Causes of death 





Morbidity (Audit standard – all cause morbidity in NSU <10%) 
The NSU morbidity rate was 14% (111/798), mainly from respiratory tract 
infection (8%) (Table 3). 
 
 
Symptomatic recurrence requiring surgery (Audit standard – rate <20%) 
Follow-up data was available for all 787 patients who underwent surgery. 
Recurrence occurred within 60 days of primary surgery in 73 patients (9%). 
The median duration of time to re-operation was 12 days (range 0-57). There 
was no significant difference in recurrence between patients who had BHC or 
craniotomy (p=0·831).  
 
We determined variables associated with symptomatic recurrence in the 684 
patients who underwent de novo BHC for whom data was available, using 
logistic regression (Table 4). Sixteen patients for whom BHC was for a CSDH 
recurrence were excluded from analysis.  
 
Drain insertion after BHC, (p=0.011, odds ratio-0.414) and a higher 
preoperative GCS (p=0.008, OR=0.859) were predictive of reduced recurrence 
after controlling for the variables shown in Table 4. These same variables 
remained predictive of recurrence when all 772 BHC and craniotomy patients 
were considered together (p=0·0003, OR=0·347 and p=0·002, OR=0·855, 
respectively).  
 
We dichotomized the 684 BHC patients according to whether they had 
unilateral or bilateral CSDH. 157 of 202 patients documented to have bilateral 
CSDH underwent bilateral BHC. In patients with unilateral BHC a higher pre-
operative GCS (p=0.006, OR=0.839) and drain insertion after BHC (p=0.004, 
OR=0.317) were still predictive of reduced recurrence. In the bilateral BHC 




Table 1). Bilateral BHC was not an independent risk factor for recurrence 
(p=0.867). 
 
There was no significant difference in recurrence rates between patients 
having one burr hole (10%) or more than one burr hole (8%) for unilateral 
CSDH (p=0.875) when controlling for the other variables. Antiplatelet 
medication use preoperatively, the administration of high flow oxygen in the 
post-operative period and bed rest did not independently significantly affect 
recurrence, (p=0.266, p=0.811, p=0.586, respectively), even when the BHC 
cohort was divided into unilateral and bilateral CSDH groups (Table 4, 
Supplementary Tables 1 and 2). The pre-operative appearance on CT imaging 
of a mixed density subdural collection, rather than a homogeneously isodense 
or hypodense clot, did not predict recurrence (p=0.293) (Table 4).  
  
 
Functional outcome (Audit standard – unfavourable mRS (4-6) at discharge 
from NSU <30%) 
Modified Rankin Score (mRS) data was available for 798 patients at the point 
of discharge. An unfavourable mRS (4-6) occurred in 176 patients (22%). The 
Median mRS score was 2, compared to 3 preoperatively (Figure 1). Factors 
predicting unfavourable mRS were determined in the 684 patients who had de 
novo BHC using logistic regression; 148 of these patients had an unfavorable 
mRS (Table 5).  
 
In the BHC group a favourable pre-operative mRS (equal to or less than 3) 
was independently predictive of a favourable mRS at discharge (p<0·00001, 
OR=2.13), as was drain insertion (p=0.048), good pre-operative GCS (p=0.01) 
and lower age (p=<0·00001); the average age of patients with a favourable 
mRS was 76 years (range 65-83), compared to 84 years (76-88) for those with 
an unfavorable mRS. Prescribed post-operative bed rest predicted a poor 




did not predict recurrence, more than one burr hole did predict a favourable 
functional outcome (p=0.020). Pre-operative mid-line shift did not significantly 
correlate with functional outcome (p=0·857). 
 
The same factors remained significant predictors of poor outcome when the 
BHC patients were considered along with the craniotomy patients. When 
patients with unilateral or bilateral CSDH were examined separately, age and 
initial MRS remained significant in both groups (p<0.0001) (Supplementary 
Tables 3 and 4). In the unilateral BHC only group bedrest (p=0.001, 
OR=2.637), drain insertion (p=0.002, OR=0.320), increased in significance, 
multiple burr holes was unchanged (p=0.030, OR=0.407), and pre-operative 
GCS became almost non-significant (p=0.054, OR=0.887). 
 
 
Length of stay and Discharge destination 
 
The median length of NSU stay was 7 days (range 1-179); there was no 
statistical difference between BHC and craniotomy. At NSU discharge, 47% of 
patients (358) were transferred to a local hospital for ongoing care whilst 49% 





This was the BNTRC’s first study and represents the largest prospective, 
observational, multi-centre study of CSDH management, NSU outcomes and 
60-day recurrence rates.  
 
The BNTRC was established by neurosurgical trainees in 2012 to improve 
research by combining the efforts of trainees in each of the UK and Ireland’s 




individuals; study leads devise the project protocol and invite collaborative 
members to join a steering group. Individual trainees in each NSU volunteer 
as data collectors. Both authorship and collaborator status on publications is 
defined in advance. Upon project completion the data becomes available to all 
collaborating members to permit further analysis.  
 
This study provides valuable insights into current management of patients with 
CSDH. It will inform contemporary practice. It validates in a real world setting 
the 2009 randomized controlled trial that demonstrated the effectiveness of 
subdural drain insertion.21 Other key observations should be validated in 
prospective trials. The study defines the current standard of care for patients 
with symptomatic CSDHs as burr-hole drainage with insertion of a subdural 
drain for 24-48 hours. There was no clear preference for prescribed bed rest 
or high flow oxygen in the postoperative period; bed rest was actually 
associated with unfavourable functional outcome.  
 
Current practice exceeded pre-defined audit standards for functional outcome 
at discharge, in-NSU mortality and 60-day post-operative symptomatic CSDH 
recurrence. However, the 14% incidence of postoperative morbidity was 
greater than the audit standard of less than 10%. This may reflect better data 
collection in our prospective study compared to existing retrospective 
studies.  Interestingly, the previously largest series (retrospective) of operated 
cases of CSDH reported 19·6% morbidity.10 There is nevertheless an 
opportunity to optimise care for CSDH patients, many of whom are elderly with 
multiple co-morbidities. There may be parallels to achieving this in the way that 
changes to peri-operative care of patients with neck of femur fractures 
reduced mortality in that vulnerable population.13 The BNTRC is therefore 
collaborating on a prospective study to examine how to optimise peri-operative 
factors in CSDH patient management. 
 




patient’s Consultant neurosurgeon, based on clinical symptoms, correlated 
with imaging. The 9% rate of symptomatic recurrence we observed at 60 days 
may have underestimated the true rate if there were late recurrences, but 
previous studies suggested recurrence is most likely within this timeframe.16 
The median time to recurrence in the present study agrees with that reported 
previously.4 Our study demonstrated that only 48% of operative patients 
underwent post-operative imaging, so there may have been incidences of 
recurrence that did not reach clinical significance, but would have been 
detected radiologically. Since the need for re-do surgery is based on 
symptomatic recurrence, radiological recurrence alone is of less importance. 
 
We observed that the number of burr holes was not an independent risk factor 
for CSDH recurrence after BHC, but single burr holes were associated with 
poorer functional outcomes at discharge. Pre-operative mRS was not 
predictive of the number of burr holes used in BHC, and the reason for the 
poorer functional outcomes is not clear. Previous retrospective studies have 
suggested that a single burr hole is as effective as two in selected cases. 11,12 
Future studies should interrogate this further. A single burr hole may be 
preferential if associated with reduced operative length and in turn post-
operative morbidity, but this has yet to be demonstrated.  
 
More than one burr hole may traditionally be preferred where there is a mixed 
density subdural collection (mixed between hyperdense and 
isodense/hypodense material). This is because the hyperdense material 
represents more acute blood that is thicker than isodense/hypodense blood 
and does not discharge as easily from a single burr hole. However, our study 
identified that the radiological appearance of the subdural collection was not 
predictive of symptomatic recurrence. This may be because the goal of 
surgery is to reduce the mass effect from the CSDH, not necessarily to remove 
the haematoma altogether; the residual subdural collection can resolve 




interestingly we observed no correlation between subdural density and the 
number of burr holes used for BHC.   
 
Evidence for the benefit of corticosteroids in CSDH management remains 
scarce. Our study documented steroid use in only a small proportion of 
patients. The effect of dexamethasone on reduction in reoperation rate of 
CSDH is the focus of a several ongoing studies, including a RCT comparing 
dexamethasone to placebo after BHC supported by the BNTRC.  
 
Anticoagulant and antiplatelet use have been implicated in both the 
development and recurrence of CSDH. 5  In our study 43% of the patients 
transferred to a NSU for treatment were taking an antiplatelet or anticoagulant 
medication. Strategies for the preoperative optimisation of platelet function and 
coagulation in these patients varied greatly, but the pre-operative prescription 
of antiplatelet agents was not an independent risk factor for recurrence. The 
impact of anti-coagulant agents was not examined, as all patients on these 
agents had their INR corrected pre-operatively. Although the use of antiplatelet 
agents was not observed to be associated with recurrence, the heterogeneity 
of timing of discontinuing medication and of reversal strategies suggests this 
observation should be interpreted cautiously. Nevertheless, it remains feasible 
that some patients may not need to discontinue their medication for the 
traditional ‘7 days’ before burr-hole surgery. This could be important, because 
delay in recommencing these therapies is associated with thromboembolic risk 
and delay to surgery whilst managing anticoagulant and antiplatelet therapies 
may also be associated with increased morbidity.  
 
Although our observations are based on UK and Ireland data the results will 
be of interest internationally, because CSDH is common worldwide.  There will 
undoubtedly be variations between countries in the preference for some aspects of 
CSDH management that were not well represented in UK practice, such as 




studies to develop an evidence base to CSDH management should include all these 
factors. 
 
There are some limitations to our study. For example, we captured data from 
patients managed in NSUs so do not know the natural history of patients with 
CSDH managed in hospitals without NSUs. We examined relatively short-term 
outcome measures and longer-term outcome measures such as 6-month 
functional status and mortality rate would be valuable. Our patient cohort was 
skewed to management with BHC, so we could not make a meaningful 
analysis of variables predicting outcome in the craniotomy subgroup. In 
addition, our study demonstrated that surgical drainage of CSDH is performed 
almost exclusively by trainee neurosurgeons and senior house officers. This is 
clearly standard practice in the UK and a previous study has found not 
association between seniority of surgeon and post-operative recurrence of 
CSDH. 20 It should also be noted that it is our experience that a Consultant 
neurosurgeon is always the person to make a decision to proceed to surgery 
and is available if needed. The question may nevertheless be raised as to 
whether patient outcomes would be different if Consultant surgeons were the 






We have defined the preferred strategy for treating symptomatic CSDH as burr 
hole drainage with post-operative closed drainage system. We have observed 
that many variations in practice do not significantly impact outcome. Further 
research is required to examine these relationships in more detail and to 
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Figure 1. A comparison of proportion of all patients with a given modified 
Rankin Score (mRS) in the pre and post-operative patient cohorts. The graph 
demonstrates the shift to better functional status on discharge compared to 
status on admission to NSU. 
 
